Mortality in patients with Clostridium difficile infection correlates with host pro-inflammatory and humoral immune responses
- PMID: 23722431
- DOI: 10.1099/jmm.0.058479-0
Mortality in patients with Clostridium difficile infection correlates with host pro-inflammatory and humoral immune responses
Abstract
Host anti-toxin immune responses play important roles in Clostridium difficile disease and outcome. The relationship between host immune and inflammatory responses during severe C. difficile infection (CDI) and the risk of mortality has yet to be defined. We aimed to investigate the host systemic IgG anti-toxin immune responses, the in vitro cytotoxicity of the infecting C. difficile ribotyped strain, and the host inflammatory markers and their relationship to CDI disease severity and risk of mortality. Inflammatory markers, co-morbidities and CDI outcomes were recorded in a prospective cohort of 150 CDI cases. Serum anti-cytotoxin A (TcdA) and anti-TcdB IgG titres were measured by ELISA and the infecting C. difficile isolate was ribotyped and the in vitro cytotoxin titre assessed. A low median anti-TcdA IgG titre was significantly associated with 30-day all-cause mortality (P<0.05). Ribotype 027 isolates were significantly more toxinogenic than other ribotypes (P<0.00001). High cytotoxin titres correlated with increased inflammatory markers but also higher anti-TcdA and -TcdB (P<0.05) IgG responses resulting in a lower risk of mortality. On multivariate analysis, predictors of mortality were peak white cell count >20 × 10(9) l(-1) [odds ratio (OR) 11.53; 95 % confidence interval (CI) 2.38-55.92], creatinine concentration >133 µmol l(-1) (OR 6.54; 95 % CI 1.47-29.07), Horn's index >3 (OR 4.09; 95 % CI 0.76-22.18) and low anti-TcdA IgG (OR 0.97; 95 % CI 0.95-0.99), but not ribotype, cytotoxin titre or anti-TcdB IgG. Thus, host pro-inflammatory and humoral responses correlate with the cytotoxin titre of the infecting strain and effective anti-toxin immune responses reduce the risk of mortality.
Similar articles
-
Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.J Med Microbiol. 2013 Sep;62(Pt 9):1394-1404. doi: 10.1099/jmm.0.056796-0. Epub 2013 Mar 21. J Med Microbiol. 2013. PMID: 23518659
-
Humoral immune response as predictor of recurrence in Clostridium difficile infection.Clin Microbiol Infect. 2014 Dec;20(12):1323-8. doi: 10.1111/1469-0691.12769. Epub 2014 Dec 12. Clin Microbiol Infect. 2014. PMID: 25041274
-
Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.PLoS One. 2016 Jun 23;11(6):e0157970. doi: 10.1371/journal.pone.0157970. eCollection 2016. PLoS One. 2016. PMID: 27336843 Free PMC article.
-
Enterotoxic Clostridia: Clostridioides difficile Infections.Microbiol Spectr. 2019 May;7(3):10.1128/microbiolspec.gpp3-0015-2018. doi: 10.1128/microbiolspec.GPP3-0015-2018. Microbiol Spectr. 2019. PMID: 31124432 Free PMC article. Review.
-
Adaptive immune response to Clostridium difficile infection: A perspective for prevention and therapy.Eur J Immunol. 2018 Mar;48(3):398-406. doi: 10.1002/eji.201747295. Epub 2018 Jan 19. Eur J Immunol. 2018. PMID: 29272036 Review.
Cited by
-
[Clostridium difficile infection : What is currently available for treatment?].Internist (Berl). 2016 Dec;57(12):1182-1190. doi: 10.1007/s00108-016-0149-0. Internist (Berl). 2016. PMID: 27796474 German.
-
Defining the black box: a narrative review of factors associated with adverse outcomes from severe Clostridioides difficile infection.Therap Adv Gastroenterol. 2021 Oct 8;14:17562848211048127. doi: 10.1177/17562848211048127. eCollection 2021. Therap Adv Gastroenterol. 2021. PMID: 34646358 Free PMC article. Review.
-
Retrospective Analysis of Clostridioides difficile Infection Rates and Outcomes in Hospitalized Patients during the COVID-19 Pandemic: A Unicenter Study in Reus, Spain.J Clin Med. 2024 May 9;13(10):2799. doi: 10.3390/jcm13102799. J Clin Med. 2024. PMID: 38792341 Free PMC article.
-
The role of the humoral immune response to Clostridium difficile toxins A and B in susceptibility to C. difficile infection: a case-control study.Anaerobe. 2014 Jun;27:82-6. doi: 10.1016/j.anaerobe.2014.03.011. Epub 2014 Apr 5. Anaerobe. 2014. PMID: 24708941 Free PMC article.
-
A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection.J Vis Exp. 2018 Jun 15;(136):57399. doi: 10.3791/57399. J Vis Exp. 2018. PMID: 29985307 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources